个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Li Guiling[1] * ; Li Xiaofan[2] ; Yin Rutie[3] ; Feng Mei[4] ; Zuo Jing[5] ; Wei Shuqing[6] ; Kang Shan[7] ; Sun Hongmei[8] ; Li Xiumin[9] ; Wang Yili[10] ; Zhang Yunyan[11] ; Sun Li[12] ; Lin Daren[13] ; Ruan Xiaohong[13] ; Zhu Zhitu[14] ; Jiang Kui[15] ; Liu Hu[16] ; Wang Wei[17] ; Hao Deshun[18] ; Chen Ying[18] ; Xiang Silong[18] ; Niu Miao[18] ; Wu Lingying[19] ;
机构： [1]Department of Gynecologic Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China. [3]Department of Obstetrics and Gynecology, West China Second University Hospital, Chengdu, Sichuan, China. [4]Department of Gynecology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China. [5]Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [6]Department of Geriatrics, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China. [7]Department of Obstetrics and Gynecology, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, Hebei, China. [8]Department of Oncology, Jiamusi Cancer and Tuberculosis Hospital, Jiamusi, Heilongjiang, China. [9]Department of Gynecologic Oncology, Linyi Cancer Hospital, Linyi, Shandong, China. [10]Department of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China. [11]Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. [12]Department of Gynecologic Oncology, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao Central Hospital, Qingdao, Shandong, China. [13]Department of Oncology, Jiangmen Central Hospital, Jiangmen, Guangdong, China. [14]Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China. [15]Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. [16]Department of Oncology, The First Affiliated Hospital of USTC, Anhui Provincial Cancer Hospital, Hefei, Anhui, China. [17]Department of Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. [18]CSPC Zhongqi Pharmaceutical Technology Co., Ltd, Shijiazhuang, Hebei, China. [19]Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: wulingying@csco.org.cn.
出处：
DOI： 10.1016/j.ygyno.2024.10.001
ISSN：

摘要：
Platinum-based chemotherapy with or without bevacizumab is the first-line treatment for patients with recurrent or metastatic cervical cancer (r/mCC), and the treatment options are limited for r/mCC after first-line treatment. Enlonstobart (SG001) is a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody. Previous phase Ib study demonstrated that SG001 had a promising efficacy in patients with PD-L1 positive r/mCC.In this multicenter, single-arm, open-label, phase II study, eligible patients were ≥ 18 years with PD-L1-positive cervical cancer who had progression on or intolerance to the first-line platinum-based chemotherapy. Patients received SG001 240 mg every two weeks for 24 months or until disease progression, intolerable toxicities, or other study discontinuation criteria were met. The primary endpoint was confirmed objective response rate (ORR) assessed by RECIST version 1.1 by independent review committee.107 patients were enrolled with median age of 53 years (range 26-72). 64.5 % of patients had a ECOG of 1. After a median follow-up of 14.0 months (range 0.4-21.9), confirmed ORR was 29.0 %, with two complete responses and twenty-nine partial responses. The disease control rate was 54.2 %. Median duration of response was 16.6 months (95 % CI 10.8-NA), median progression free survival was 3.1 months (95 % CI 2.2-6.9). Median overall survival was not reached. 104 patients (97.2 %) experienced at least one treatment emergent adverse events TEAEs, of which 38 patients (35.5 %) had grade 3 or higher TEAEs. The most common treatment-related adverse events were leukopenia (19.6 %), increased aspartate aminotransferase (18.7 %), anemia (17.8 %), increased alanine aminotransferase (15.9 %), hypothyroidism (15.0 %), neutropenia (15.0 %), and hyperthyroidism (11.2 %).SG001 monotherapy demonstrated durable anti-tumor activity with acceptable safety in patients with PD-L1 positive r/mCC with progression on or intolerance to the first-line platinum-based chemotherapy.ClinicalTrials.gov (NCT04886700).Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 2 区 医学
小类 | 1 区 妇产科学 2 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 OBSTETRICS & GYNECOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Department of Gynecologic Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
推荐引用方式(GB/T 7714)：
Li Guiling,Li Xiaofan,Yin Rutie,et al.Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer[J].Gynecologic Oncology.2024,191:165-171.doi:10.1016/j.ygyno.2024.10.001.
APA：
Li Guiling,Li Xiaofan,Yin Rutie,Feng Mei,Zuo Jing...&Wu Lingying.(2024).Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.Gynecologic Oncology,191,
MLA：
Li Guiling,et al."Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer".Gynecologic Oncology 191.(2024):165-171

资源点击量：53080 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号